Search

Your search keyword '"Beelen D"' showing total 983 results
Start Over Author "Beelen D"
983 results on '"Beelen D"'

56. SIGNIFICANCE OF ACHIEVING SECOND CHRONIC PHASE PRIOR TO ALLOGENEIC STEM CELL TRANSPLANT FOLLOWING TYROSINE KINASE INHIBITOR THERAPY: A RETROSPECTIVE STUDY FROM THE CHRONIC MALIGNANCY WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION: PH-P099

Author

Milojkovic, D., Szydlo, R., Hoek, J., Beelen, D., Hamladji, R., Kyrcz-Krzemien, S., Bacigalupo, A., Niederwieser, D., Tischer, J., Schwerdtfeger, R., Volin, L., Gurman, G., Greinix, H., Chalandon, Y., Kroeger, N., and Olavarria, E.

Published
2014

60. PROGNOSTIC SIGNIFICANCE OF EBMT SCORE FOR CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE ERA OF TYROSINE KINASE INHIBITOR THERAPY: A RETROSPECTIVE STUDY FROM THE CHRONIC MALIGNANCY WORKING PARTY OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION (EBMT): PH-O064

Author

Milojkovic, D., Szydlo, R., Hoek, J., Beelen, D., Hamladji, R., Kyrcz-Krzemien, S., Bacigalupo, A., Niederwieser, D., Tischer, J., Schwerdtfeger, R., Volin, L., Gurman, G., Greinix, H., Chalandon, Y., Kroeger, N., and Olavarria, E.

Published
2014

61. LONG-TERM FOLLOW-UP DATA SUPPORT THE CURATIVE POTENTIAL OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE ANALYSIS FROM THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT: PH-O063

Author

van Gelder, M., de Wreede, L., Henseler, A., van Biezen, A., Niederwieser, D., Karas, M., Andersen, N. S., Gramatzki, M., Dreger, P., Bunjes, D., Petersen, E., Potter, M., Beelen, D., Yakoub-Agha, I., Cornelissen, J. J., Russell, N. H., Finke, J., Maertens, J., Blaise, D., Paneesha, S., Vitek, A., Bornhäuser, M., Schoenland, S., Kröger, N., and Schetelig, J.

Published
2014

62. IMPACT OF CYTOGENETIC USING THE IPSS REVISED CYTOGENETIC CLASSIFICATION ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MDS OR AML EVOLVING FROM MDS: A RETROSPECTIVE MULTICENTER STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT: PH-O012

Author

Koenecke, C., Göhring, G., de Wreede, L., van Biezen, A., Scheid, C., Volin, L., Maertens, J., Finke, J., Schaap, N. P. M., Robin, M., Passweg, J., Cornelissen, J., Beelen, D., Heuser, M., de Witte, T., and Kröger, N.

Published
2014

65. OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS

Author

Dreger, P., primary, Martus, P., additional, Holtick, U., additional, Ayuk, F., additional, Wagner‐Drouet, E. M., additional, Wulf, G., additional, Marks, R., additional, Penack, O., additional, Koenecke, C., additional, von Bonin, M., additional, von Tresckow, B., additional, Stelljes, M., additional, Baldus, C., additional, Vucinic, V., additional, Mougiakakos, D., additional, Topp, M., additional, Wolff, D., additional, Schroers, R., additional, Schmitt, M., additional, Schmitt, T., additional, Lengerke, C., additional, Thomas, S., additional, Beelen, D. W., additional, and Bethge, W., additional

Published
2021
Full Text
View/download PDF

72. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)

Author

Hehlmann, Rüdiger, Voskanyan, Astghik, Lauseker, Michael, Pfirrmann, Markus, Kalmanti, Lida, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Haferlach, Claudia, Schlegelberger, Brigitte, Fabarius, Alice, Seifarth, Wolfgang, Spieß, Birgit, Wuchter, Patrick, Krause, Stefan, Kolb, Hans Jochem, Neubauer, Andreas, Hossfeld, Dieter K., Nerl, Christoph, Gratwohl, Alois, Baerlocher, Gabriela M., Burchert, Andreas, Brümmendorf, Tim H., Hasford, Jörg, Hochhaus, Andreas, Saußele, Susanne, Baccarani, Michele, von Weikersthal, L. Fischer, Hahn, M., Schlimok, G., Reichert, D., Janssen, J., Martens, U., Majunke, P., Reichert, Peter, Neben, K., Korsten, S., Scholz, Ch, Oldenkott, B., Heßling, J., Kingreen, D., Sperling, C., Schelenz, C., Blau, I., Urmersbach, A., Ludwig, W., Le Coutre, P., Arnold, R., de Wit, M., Pezzutto, A., Schäfer, E., Schroers, R., Lochter, A., Behringer, D., Ko, Y., Weidenhöfer, S., Verbeek, W., Brossart, P., Trenn, G., Pommerien, W., Krauter, J., Doering, G., Munzinger, H., Diekmann, C., Hertenstein, B., Stier, S., Möller-Faßbender, F., Hänel, M., Zöller, T., Lamberti, C., Koch, B., Henzel, A., Wagner, S., Schmalenbach, A., Hoffknecht, M., Ehninger, G., Kiani, A., Illmer, T., Aul, C., Flaßhove, M., Henneke, F., Simon, M., Müller, L., Becker, H., Janz, R., Eckart, M. J., Fuchs, R., Schlegel, F., Wattad, M., Rudolph, R., Beelen, D. W., Lindemann, A., Linck, D., Wassman, Jäger, E., Al-Batran, S., Reiber, T., Waller, C. F., Hoeffkes, H., Schulz, L., Tajrobehkar, K., Mittermüller, J., Pralle, H., Runde, V., Hoyer, A., Tessen, H., Trümper, L., Schmidt, C., Sieber, M., Eschenburg, H., Depenbusch, R., Rösel, S., Lindemann, H. W., Wolf, H., Spohn, C., Moeller, R., Hossfeld, D., Zander, A., Schafhausen, P., Köster, H., Hollburg, W., Schmitz, N., Dürk, H., Hemeier, M., Grote-Metke, A., Weischer, H., Bechtel, B., Balleisen, L., Sosada, M., Ho, A., Petersen, V., Dengler, J., Bildat, S., Hahn, L., Dietzfelbinger, H., Gröschel, W., Bartholomäus, A., Freier, W., Sievers, B., Pfreundschuh, I. M., Herrmann, T., Fauser, A., Menzel, J., Kemmerling, M., Hansen, R., Link, H., Schatz, M., Bentz, M., Prümmer, O., Kneba, M., Heymanns, J., Schmitz, S., Scheid, C., Lollert, A., Neise, M., Planker, M., Stauch, M., Schröder, M., Kempf, B., Vehling-Kaiser, U., Kremers, S., Köchling, G., Hartmann, F., Neuhaus, T., Fetscher, S., Kämpfe, D., Heil, G., Uppenkamp, M., Goldmann, B., Huber, T. Fischer, Hieber, U., Plöger, C., Griesshammer, M., Lange, C., Göttler, B., Lunscken, C., Schiel, X., Scheidegger, C., Stötzer, O., Hitz, H., Schick, H., Völkl, S., Spiekermann, K., Berdel, W., Hebart, H., Ladda, E., Schmidt, P., Burkhardt, U., Hentschke, S., Falge, C., Reschke, D., Köhne, C. A., Müller-Naendrup, C., Sauer, M., Frühauf, S., Ranft, K., Dencausse, Y., Sandritter, B., Baake, G., Hofknecht, M., Dengler, R., Edinger, M., Schenk, M., Wehmeier, A., Weidelich, H. P., Pihusch, R., Stahlhut, K., Baldus, M., Matzdorff, A., Geer, T., Schanz, S., Käfer, G., Gassmann, W., Priebe-Richter, C., Demandt, M., Springer, G., Fiechtner, H., Denzlinger, C., Schleicher, J., Assman, D., Gaeckler, R., Adam, G., Waladkhani, A., Rendenbach, B., Forstbauer, H., Kanz, L., Jacki, S., Stegelmann, F., Kalhori, N., Nusch, A., Langer, W., Müller, F., Brettner, S., Uebelmesser, B., Kamp, T., Schadeck-Gressel, C., Josten, K., Klein, O., Schwerdtfeger, R., Baurmann, H., Strotkötter, H., Fett, W., Raghavachar, A., Maintz, C., Goebler, M. C., Schlag, R., Elsel, W., Wernli, M., Heim, D., Wuillemin, W., Hess, U., Gmür, J., and Mayer, J.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020
Full Text
View/download PDF

73. Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years

Author

Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang Blau I, Potter V, Niittyvuopio R, Socié G, Blaise D, Sanz J, Ciceri F, Abou Dalle I, Spyridonidis A, Bug G, Esteve J, Savani BN, Nagler A, and Mohty M

Subjects
surgical procedures, operative, endocrine system diseases, hemic and lymphatic diseases, neoplasms
Abstract

Relapsed acute myeloid leukemia (AML) post allogeneic-hematopoietic-cell-transplantation (allo-HCT) has a dismal prognosis.

Published
2020

75. Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party

Author

Samarasinghe, S, Clesham, K, Iacobelli, S, Sbianchi, G, Knol, C, Hamladji, R-M, Socié, G, Aljurf, M, Koh, M, Sengeloev, H, Dalle, J-H, Robinson, S, Van Lint, MT, Halkes, CJ, Beelen, D, Mufti, GJ, Snowden, J, Blaise, D, Peffault de Latour, R, Marsh, J, Dufour, C, Risitano, AM, Severe Aplastic Anaemia Working Party of the EBMT, Samarasinghe, Sujith, Clesham, Katherine, Iacobelli, Simona, Sbianchi, Giulia, Knol, Cora, Hamladji, Rose-Marie, Socié, Gerard, Aljurf, Mahmoud, Koh, Mickey, Sengeloev, Henrik, Dalle, Jean-Hugue, Robinson, Stephen, Van Lint, Maria Teresa, Halkes, Constantijn J. M., Beelen, Dietrich, Mufti, Ghulam J., Snowden, John, Blaise, Didier, de Latour, Regis Peffault, Marsh, Judith, Dufour, Carlo, and Risitano, Antonio M

Subjects
Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Adolescent, Anemia, T-Lymphocytes, medicine.medical_treatment, Medizin, Graft vs Host Disease, Hematopoietic stem cell transplantation, Lower risk, Gastroenterology, Lymphocyte Depletion, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Living Donors, medicine, Humans, Young adult, Child, Alemtuzumab, Aged, Antilymphocyte Serum, Retrospective Studies, Transplant Conditioning, business.industry, Hematopoietic Stem Cell Transplantation, Immunization, Passive, Anemia, Aplastic, Infant, Hematology, Middle Aged, Settore MED/15, medicine.disease, Transplantation, Settore MED/01, Treatment Outcome, surgical procedures, operative, Child, Preschool, 030220 oncology & carcinogenesis, Female, business, 030215 immunology, medicine.drug
Abstract

We retrospectively analyzed the outcomes of 1837 adults and children with severe aplastic anemia (SAA) who underwent matched sibling donor (MSD) and matched unrelated donor (MUD) hemopoietic stem cell transplantation (HSCT) between 2000 and 2013. Patients were grouped by transplant conditioning containing either anti‐thymocyte globulin (ATG) (n = 1283), alemtuzumab (n = 261), or no serotherapy (NS) (n = 293). The risks of chronic GvHD were significantly reduced when ATG or alemtuzumab were compared with NS (P = .021 and .003, respectively). Acute GVHD was significantly reduced in favor of alemtuzumab compared with ATG (P = .012) and NS (P < .001). By multivariate analysis, when compared with ATG, alemtuzumab was associated with a lower risk of developing acute (OR 0.262; 95% CI 0.14‐0.47; P < .001) and chronic GVHD (HR 0.58; 95% CI 0.35‐0.94; P = .027). OS was significantly better in ATG and alemtuzumab patients compared with NS (P = .010 and .025). Our data shows inclusion of serotherapy in MSD and MUD HSCT for patients with SAA reduces chronic GVHD and provides a survival advantage over patients not receiving serotherapy. Notably, alemtuzumab reduced the risk of acute and chronic GvHD compared with ATG and indicates that alemtuzumab might be the serotherapy of choice for MSD and MUD transplants for SAA.

Published
2018
Full Text
View/download PDF

76. Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

Author

Carre, Martin, Porcher, R., Finke, J., Ehninger, G., Koster, L, Beelen, D., Witte, T.J.M. de, Kroger, N., Robin, M., Carre, Martin, Porcher, R., Finke, J., Ehninger, G., Koster, L, Beelen, D., Witte, T.J.M. de, Kroger, N., and Robin, M.

Abstract

Contains fulltext : 217405.pdf (Publisher’s version ) (Closed access)

Published
2020

77. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first comp

Author

Schmaelter, A.-K. (Ann-Kristin), Labopin, M. (Myriam), Socie, G. (Gerard), Itälä Remes, M. (Maija), Blaise, D. (Didier), Yakoub-Agha, I. (Ibrahim), Forcade, E. (Edouard), Cornelissen, J.J. (Jan), Ganser, A. (Arnold), Beelen, D. (Dietrich), Labussière-Wallet, H. (Hélène), Passweg, J. (Jakob Robert), Savani, B.N. (Bipin N.), Schmid, C. (Christoph), Nagler, A. (Arnon), Mohty, M. (Mohamad), Schmaelter, A.-K. (Ann-Kristin), Labopin, M. (Myriam), Socie, G. (Gerard), Itälä Remes, M. (Maija), Blaise, D. (Didier), Yakoub-Agha, I. (Ibrahim), Forcade, E. (Edouard), Cornelissen, J.J. (Jan), Ganser, A. (Arnold), Beelen, D. (Dietrich), Labussière-Wallet, H. (Hélène), Passweg, J. (Jakob Robert), Savani, B.N. (Bipin N.), Schmid, C. (Christoph), Nagler, A. (Arnon), and Mohty, M. (Mohamad)

Abstract

Following chemotherapy, secondary acute myeloid leukemia (sAML), occurring after antecedent hematologic diseases, previous chemotherapy or radiation, has an inferior prognosis compared with de novo AML. To define the outcome of sAML in the context of allogeneic stem cell transplantation (alloSCT), a retrospective, registry-based comparison was performed, including 11,439 patients with de novo and 1325 with sAML. Among transplants in first complete remission (CR1) (n = 8,600), the 3-year cumulative incidence of relapse (RI) and non-relapse mortality (NRM) was 28.5% and 16.4% for de novo, and 35% and 23.4% for sAML. Three-year overall survival (OS), leukemia-free survival (LFS) and Graft-versus-Host Disease/relapse-free survival (GRFS) was 60.8%, 55.1%, and 38.6% for de novo, and 46.7%, 41.6%, and 28.4% for sAML, respectively. In multivariate analysis, sAML was associated with a lower OS (HR = 1.33 [95% CI = 1.21-1.48]; p < 10-5), LFS (HR = 1.32 [95% CI = 1.19-1.45]; p < 10-5) and GRFS (HR = 1.2 [95% CI = 1.1-1.31]; p < 10-4) and higher NRM (HR = 1.37 [95% CI = 1.17-1.59]; p < 10-4) and RI (HR = 1.27 [95% CI = 1.12-1.44]; p < 10-3). Results of the Cox model were confirmed in a matched-pair analysis. In contrast, results did not differ between de novo and sAML after alloSCT in induction failure or relapse. Hence, this analysis identified sAML as an independent risk factor for outcome after alloSCT in CR1.

Published
2020
Full Text
View/download PDF

78. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Halaburda, K, Labopin, M, Mailhol, A, Socie, G, Craddock, C, Aljurf, M, Beelen, D, Cornelissen, Jan, Bourhis, J H, Labussiere-Wallet, H, Blaise, D, Gedde-Dahl, T, Gilleece, M, Yakoub-Agha, I, Mufti, G, Esteve, J, Mohty, M, Nagler, A, Halaburda, K, Labopin, M, Mailhol, A, Socie, G, Craddock, C, Aljurf, M, Beelen, D, Cornelissen, Jan, Bourhis, J H, Labussiere-Wallet, H, Blaise, D, Gedde-Dahl, T, Gilleece, M, Yakoub-Agha, I, Mufti, G, Esteve, J, Mohty, M, and Nagler, A

Published
2020

79. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia

Author

Schmaelter, AK, Labopin, M, Socie, G, Itala-Remes, M, Blaise, D, Yakoub-Agha, I, Forcade, E, Cornelissen, Jan, Ganser, A, Beelen, D, Labussiere-Wallet, H, Passweg, J, Savani, BN, Schmid, C, Nagler, A, Mohty, M, Schmaelter, AK, Labopin, M, Socie, G, Itala-Remes, M, Blaise, D, Yakoub-Agha, I, Forcade, E, Cornelissen, Jan, Ganser, A, Beelen, D, Labussiere-Wallet, H, Passweg, J, Savani, BN, Schmid, C, Nagler, A, and Mohty, M

Published
2020

80. Erratum: Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

Author

Robin, M, Porcher, R, Zinke-Cerwenka, W, van Biezen, A, Volin, L, Mufti, G, Craddock, C, Finke, J, Richard, C, Passweg, J, Peniket, A, Maertens, J, Sucak, G, Gedde-Dahl, T, Vitek, A, Nagler, A, Blaise, D, Beelen, D, Maillard, N, Schwerdtfeger, R, de Witte, T, and Kroger, N

Published
2017
Full Text
View/download PDF

97. Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells

Author

Ottinger, H., Müller, C., Goldmann, S., Albert, E., Arnold, R., Beelen, D., Blasczyk, R., Bunjes, D., Casper, J., Ebell, W., Ehninger, G., Eiermann, T., Einsele, H., Fauser, A., Ferencik, S., Finke, J., Hertenstein, B., Heyll, A., Klingebiel, T., Knipper, A., Kremens, B., Kolb, H., Kolbe, K., Lenartz, E., Lindemann, M., Müller, C., Mytilineos, J., Niederwieser, D., Runde, V., Sayer, H., Schaefer, U., Schmitz, N., Schröder, S., Schulze-Rath, R., Schwerdtfeger, R., Siegert, W., Thiele, B., Zander, A., and Grosse-Wilde, H.

Published
2001
Full Text
View/download PDF

100. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia

Author

Lengfelder, E, Reichert, A, Schoch, C, Haase, D, Haferlach, T, Löffler, H, Staib, P, Heyll, A, Seifarth, W, Saussele, S, Fonatsch, C, Gassmann, W, Ludwig, W-D, Hochhaus, A, Beelen, D, Aul, C, Sauerland, M-C, Heinecke, A, Hehlmann, R, Wörmann, B, Hiddemann, W, and Büchner, T

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results